Poststroke XXXX : natural history and immediate management.

@entity1 @entity64 @entity2690 @entity4053 @entity972 @entity4854 @entity413
BACKGROUND AND PURPOSE: Poststroke @entity4854 (PSH) is a frequent finding for which there is currently no evidence to justify routine treatment. The United Kingdom @entity413 @entity2690 in @entity64 Trial (GIST-UK) is the only trial of @entity413 modulation in @entity64 from which evidence can be derived for the immediate management of PSH. Using safety-monitoring data from the trial we aimed to describe the immediate recovery of PSH in treated and control @entity1 , thus providing evidence for the use of @entity413 / @entity972 / @entity2690 (GKI) infusions as a means of maintaining euglycemia. METHODS: GIST-UK is a multicenter randomized controlled trial of GKI or saline infusions in @entity64 @entity1 presenting with mild to moderate @entity4854 (admission plasma @entity413 , 6.0 to 17 mmol). We analyzed the capillary BM and plasma @entity413 values in the 2 treatment groups to describe the recovery of PSH and the effectiveness of the GIST treatment regimen in maintaining euglycemia. RESULTS: The majority of @entity1 have only moderate PSH (mean plasma @entity413 , 8.37+/-SD 2.13). Without specific intervention, mean plasma @entity413 levels decline spontaneously. Treatment with the GIST GKI regimen rapidly achieved euglycemia at significantly lower levels than with saline hydration alone. Euglycemia was achieved with a median of 2 changes to the GKI regimen and a low risk of @entity4053 . CONCLUSIONS: GKI infusions as described in the GIST trial are a safe and effective means of correcting PSH and maintaining euglycemia in the acute phase of @entity64 . The clinical benefits of routine management of @entity4854 remain to be determined.
